Pennsylvania 2025_0 Regular Session Status: In Committee 4 D cosponsors

HB 2545 — An Act providing for insurance coverage for vaginal estrogen for the treatment of menopausal symptoms and urinary tract infections.

Last action — Laid on the table, Sept. 29, 2026

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced May 27, 2026. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

Prognosis

Stalled 26% · moderate confidence

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

  • In Committee

    Current position in the legislative process.

  • 7 sponsors

    1 primary, 6 co-sponsors signed on.

  • Single-party support

    Sponsorship is currently within one party (4 D).

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

In plain language

The bill provides insurance coverage for vaginal estrogen treatment.

This bill mandates that insurance companies cover vaginal estrogen used to treat menopausal symptoms and urinary tract infections (UTIs). It aims to improve access to necessary treatments for affected individuals.

What this means for you
  • Consumers: This means consumers may have better access to affordable vaginal estrogen treatments for menopause and UTIs.

Summary

Insurance Coverage for Vaginal Estrogen and the Prevention of UTIs

Bill Text

What changed in the latest version

76 added · 74 removed

Plain-language change summary

The amendment removes specific exclusions from the definition of "health insurance policy," including a workers' compensation policy and an automobile medical payment policy. This change clarifies which types of insurance are categorized under health insurance, potentially affecting how these policies are treated under the bill. By excluding these specific policies, the bill may ensure that they do not fall under the same regulations or requirements intended for traditional health insurance coverage.

→
Previous
Latest
PRINTER'S NO.
PRIOR PRINTER'S NO.
3452 THE GENERAL ASSEMBLY OF PENNSYLVANIA HOUSE BILL Session of No.
3452 PRINTER'S NO.
3949 THE GENERAL ASSEMBLY OF PENNSYLVANIA HOUSE BILL Session of No.
WILLIAMS AND PARKER, MAY 27, 2026 REFERRED TO COMMITTEE ON INSURANCE, MAY 27, 2026 AN ACT Providing for insurance coverage for vaginal estrogen for the treatment of menopausal symptoms and urinary tract infections.
WILLIAMS, PARKER, ISAACSON, BOYD AND TIBURCIO, MAY 27, 2026 AS REPORTED FROM COMMITTEE ON AGING AND OLDER ADULT SERVICES, HOUSE OF REPRESENTATIVES, AS AMENDED, SEPTEMBER 29, 2026 AN ACT Providing for insurance coverage for vaginal estrogen for the treatment of menopausal symptoms and urinary tract infections.
(4) Decrease in fertility.
20260HB2545PN3949 - 2 - (4) Decrease in fertility.
20260HB2545PN3452 - 2 - (5) Loss of bone density, including osteoporosis.
(5) Loss of bone density, including osteoporosis.
A health insurance policy offered, issued or renewed in this Commonwealth after the effective date of this section shall provide coverage for vaginal estrogen for the treatment of menopausal symptoms and for the prevention of urinary tract infections.
A health insurance policy offered, issued or renewed in this Commonwealth after the effective date of this section shall provide coverage for vaginal estrogen for the treatment of menopausal symptoms and for the prevention of urinary tract infections IN INDIVIDUALS WITH MENOPAUSE.
The coverage required under this section shall, at a minimum, include coverage for all drugs, devices and combination products approved by the United States Food and Drug Administration for the provision or administration of vaginal estrogen.
The coverage required <-- under this section shall, at a minimum, include coverage for all drugs, devices and combination products approved by the United States Food and Drug Administration for the provision or administration of vaginal estrogen.
(1) For a health insurance policy for which either rates or forms are required to be filed with the department, this act shall apply to a policy for which a form or rate is first 20260HB2545PN3452 - 3 - filed on or after the effective date of this paragraph.
(1) For a health insurance policy for which either rates or forms are required to be filed with the department, this 20260HB2545PN3949 - 3 - act shall apply to a policy for which a form or rate is first filed on or after the effective date of this paragraph.
20260HB2545PN3452 - 4 -
20260HB2545PN3949 - 4 -
⬇ Download PDF
View plain text versions (2)

Action History

  1. Laid on the table, Sept. 29, 2026

  2. First consideration, Sept. 29, 2026

  3. Reported as amended, Sept. 29, 2026

  4. Re-referred to AGING AND OLDER ADULT SERVICES, June 24, 2026

  5. Reported with request to re-refer to AGING AND OLDER ADULT SERVICES, June 24, 2026

  6. Referred to INSURANCE, May 27, 2026

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 6 co-sponsors · 246 not signed on

Sponsors (1)

Co-sponsors (6)

Not signed on (246)

246 members have not signed on to this bill.

Show all 246 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB 2545 do?
Insurance Coverage for Vaginal Estrogen and the Prevention of UTIs
Who sponsors HB 2545?
HB 2545 is sponsored by BOYD, TIBURCIO, HOHENSTEIN, Melissa L. Shusterman (Democratic), Dan K. Williams (Democratic), Darisha K. Parker (Democratic), and MaryLouise Isaacson (Democratic).
What is the current status of HB 2545?
This bill is in committee in the House. Introduced May 27, 2026. It must pass committee before a floor vote.
Where can I track HB 2545?
Track HB 2545 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 2545

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 2545

Last checked for changes 8 days ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →